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Abstract
Background: Quality of life among cancer patients after diagnosis and treatment steps is an important factor in preventing further
cancer complications. Thus, appropriate tools to evaluate the quality of life among this group are required. Quality of life in Adult
Cancer Survivors (QLACS) questionnaire is a suitable tool which evaluates different aspects of life among cancer survivors.
Objectives: This study evaluated the Persian version of the QLACS questionnaire among Iranian short-survivors of breast cancer by
assessing its validity and reliability.
Methods: The QLACS was translated to Persian for this study. The questionnaire’s face and content validity were assessed by a panel
of experts by the impact score, content validity ratio, and index methods. In the next step, the questionnaire was filled out by 150
women with breast cancer who were diagnosed 1.5 - 5 years before this study. Explanatory factor analysis was performed to assess
factors. Reliability was evaluated using Cronbach’s alpha.
Results: Overall, 37 items were selected for explanatory factor analysis that had an impact score of more than 1.5, content validity
ratio (CVR) more than 0.99, and a suitable content validity index (CVI). In factor analysis, 10 factors were extracted via varimax rota-
tion, accounting for 75.8% of the total variance. Cronbach’s alpha of all the factors was more than 0.7, that was similar to the original
questionnaire.
Conclusions: We conclude that the Persian version of the QLACS questionnaire has optimal properties for the assessment of quality
of life among Iranian short-survivors of breast cancer.
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1. Background
Breast cancer is the most important type of cancer
among women worldwide, including Iran, comprising 23%
of all cancers in this group around the globe and 21.4%
in Iran (1, 2). Today, the rate of breast cancer mortality
has reduced because of advancements in its screening and
treatment methods. Thus, the percentage of patients liv-
ing with this cancer is increasing (3). An American study
showed that 89.2% of women with breast cancer were alive
after five years of cancer diagnosis (4). In another study in
Iran, 58% of women with cancer were alive after five years
of diagnosis (5). According to the national cancer defini-
tion, survivor of cancer is defined as a patient with cancer
from diagnosis to death (4). The growing number of breast
cancer survivors indicates a need for a comprehensive eval-
uation of different physical and mental aspects to prevent
or reduce cancer-related disability.
Quality of life is a good way to comprehensively eval-
uate patients’ needs, understand success or failure in the
treatment process, and prevent further complications of
the cancer (4, 6, 7). Multiple tools have been used to deter-
mine the quality of life in the active phase of the illness,
such as FACT-B and EORTC (6). EORTC QLQ-C30 question-
naire has been standardized for Iranian women (8). How-
ever, this tool cannot evaluate the patient’s quality of life af-
ter the treatment process. Thus, a tool for evaluating long-
term effects of treatment and illness on physical, psycho-
logical , cognitive and sexual conditions is required (9).
This tool should cover problems encountered at the end of
treatment, such as pain, worry about appearance, and ill-
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ness relapse (9). Quality of life in the Adult Cancer Survivor
(QLACS) questionnaire covers different aspects of patient’s.
This questionnaire includes 12 sections, seven of which are
related to the general condition of quality of life and five
sections to special conditions of cancer patients (3). This
questionnaire was first designed to evaluate the quality of
life in long survivors of cancer (6). But later studies showed
this questionnaire is suitable for short-survivors of cancer
as well (3, 4).
2. Objectives
Considering the inability of the available tools to eval-
uate the quality of life among Iranian cancer survivors at
the end of treatment and follow up stages and the ability
of QLACS questionnaire, this study was performed to eval-
uate the properties of the Persian version of QLACS ques-
tionnaire among Iranian short-survivors of breast cancer
by assessing its validity and reliability.
3. Methods
This was a cross-sectional study. The inclusion criteria
included patients diagnosed with stage I, II, or III breast
cancer 1.5 - 5 years before starting the study, having fin-
ished the active stages of treatment, being in follow up
stage, ability to read and understand Persian, and inter-
est to participate. This study was performed at Sayed al-
Shohada Hospital clinics, a referral center for cancer pa-
tients in Isfahan city in 2017. The eligibility criteria for the
center included providing accessibility to a large number
of breast cancer survivors in follow up stages. At first, the
interviewer explained the purpose of the study, the volun-
tary nature of participation, and confidentiality of infor-
mation. Then, the questionnaire was filled out by patients
who were willing to participate.
3.1. Questionnaire
The QLACS questionnaire includes 47 items catego-
rized into 12 domains rated based on a seven-point Likert
scale. It consists of seven domains related to the general
condition, including positive and negative feelings, cogni-
tive and sexual problems, pain, fatigue, and social avoid-
ance. There are five domains associated with the cancer-
specific condition. Its topics include appearance concern,
financial problems, recurrence concern, family-related dis-
tress, and cancer benefit. In this study, items were rated
based on a five-point Likert scale (i.e., never , seldom, some-
time, usually, and always) (3).
3.2. Procedure
3.2.1. Translation
In this study, we used the forward-backward method.
At first, the original version of the questionnaire was trans-
lated to Persian by two native Iranians who were proficient
in English and were aware of the research objectives. A
review session was held to make the necessary changes
and provide the first Persian version of the questionnaire.
At the backward step, the Persian version of the question-
naire was separately back-retranslated into English by two
bilingual English speakers who was aware of the study ob-
jectives. A session was held to compare translations with
the original version of the questionnaire. The final Persian
version was prepared after making the necessary changes
(10).
3.2.2. Face Validity
We used the quantitative method to evaluate the face
validity of the questionnaire. Quantitative face validity was
established by an impact score. In this method, validity
is calculated by multiplying the importance of each item
with its frequency. The importance of each item is rated
based on a Likert scale ranging from very important (5
score) to unimportant (1 score). An impact score of more
than 1.5 is considered suitable. To determine quantitative
face validity, the questionnaire was evaluated by a panel
of experts, including an internal specialist, a psychologist,
three palliative care specialists, and a specialist related to
tool making (11).
3.2.3. Content Validity
To evaluate content validity, we used content validity
ratio (CVR) for investigating items’ necessity and content
validity index (CVI) for items’ relevance.
A three-point Likert scale was used to evaluate the ne-
cessity of each item as follows: necessary (3 scores), useful
but not necessary (2 scores), not necessary (1 score). The for-
mula of content validity ratio is CVR= (Ne - N/2)/(N/2). In
this formula, N is the number of specialists, and Ne is the
number of specialists who indicated item necessity. A CVR
of more than 0.99 was meaningful and acceptable accord-
ing to the Lawshe table based on the number of panelists
(12).
The relevancy of each item was assessed by a four-point
Likert scale as follows: very relevant (4 scores), relevant (3
scores), relatively relevant (2 scores), and not relevant (1
score). The formula of the content validity index is CVI =
Nr/N. In this formula, N is the number of specialists, and Nr
is the number of specialists who selected relevant or very
relevant for each item. A CVI of more than 0.79 was consid-
ered suitable. The items with CVI between 0.7 - 0.79 were
acceptable after item modification (11).
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3.2.4. Construct Validity
We used exploratory factor analysis (EFA) for this sec-
tion. EFA is a statistical method that identifies the dimen-
sionality of structures by exploring relations between fac-
tors and items (13). This method sets the number of ques-
tionnaire domains that do not overlap with each other (14).
The suitable sample size for EFA is 3-6 cases for every item,
according to Cattell (15).
3.2.5. Reliability
We used Cronbach’s alpha coefficient to assess the reli-
ability of the questionnaire. A value of more than 0.7 was
considered suitable (14, 16).
3.3. Statistical Analysis
Descriptive statistics were used to calculate face and
content validity. EFA was used to determine construct
validity. EFA process was started with the Kaiser-Meyer-
Olkin (KMO) test that measures sampling adequacy, and
Bartlett’s test of sphericity confirmed that data collected
for EFA are suitable (13). A significant value for Bartlett’s
test of sphericity is less than 0.05 to continue EFA. Appro-
priate KMO is more than 0.6 (13). For factor extraction, prin-
ciple component analysis and varimax rotation were used.
Eigenvalue and scree plot graphics were used to determine
the number of factors to be extracted. Eigenvalue was con-
sidered more than 1 that explained variance percentage of
each factor was more than 3% (17). The reliability of the
questionnaire was calculated according to Cronbach’s al-
pha.
4. Results
The panel of experts included six specialists who evalu-
ated quantitative face validity via impact score and content
validity via CVR and CVI.
The impact score, CVR, and CVI of the questionnaire
items are shown in Table 1. One item was deleted in the face
validity stage. This item had an impact score of less than
1.5. Nine items were deleted in the content validity stage.
Seven items had a CVR of less than 0.99, and two items had
CVI less than 0.7.
Construct validity was established on 37 items via fac-
tor analysis. In this section, the questionnaire was filled
out by 150 patients who met the inclusion criteria (four
samples per item). Participants were between 30 - 68 years
old. Kaiser-Meyer-Olkin (KMO) test confirmed the sam-
pling adequacy for EFA, KMO = 0.844. Bartlett’s test of
sphericity, χ2 = 3504.456, P < 0.000 showed that correla-
tions between items were suitable to conduct EFA. Ten fac-
tors had eigenvalues greater than one, and the scree plot
is shown in Figure 1. Factor analysis extracted 10 factors via
varimax rotation, accounting for 75.8% of the total variance
(Table 2). Item 31 was transferred to the recurrence-distress
factor, and recurrence-distress and family distress factors
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Figure 1. Scree plot for the QLACS instrument
The reliability of the questionnaire was evaluated by
Cronbach’s alpha. In this section, the questionnaire was
filled out by 20 patients who met the inclusion criteria.
Cronbach’s alpha was calculated by the statistical analysis
for each factor (Table 3). Cronbach’s alpha coefficients were
more than 0.7 for all the factors.
5. Discussion
Quality of life evaluation can help to determine the
necessary interventions for improving cancer survivor’s
quality of life. Among the available tools, we used the
QLACS questionnaire because it covered different aspects
of life among cancer survivors (3). In this study, after
the translation process, we evaluated the face, content
and construct validity and reliability of the questionnaire.
Overall, 46 items had impact scores of more than 1.5; thus,
they were used to evaluate CVR and CVI validity. Nine items
were deleted in the content validity stage because of CVR
less than 0.99 (seven items) and CVI less than 0.7 (two
items). EFA extracted 10 factors from the 37 items. All of the
questionnaire domains had a Cronbach’s alpha coefficient
of more than 0.7.
According to our results, 10 items were deleted in
the face and content validity stages. One reason can be
the specialist panel that expressed their opinions subjec-
tively about items. However, specialists’ panel were in-
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Table 1. Impact Score, CVR1 and CVI2 Results Among Breast Cancer Survivors
N Question Impact Score CVR CVI
1 You had the energy to do the things you wanted to do 4.8 1 1
2 You had difficulty doing activities that require concentrating. 3.56 1 1
3 You were bothered by having a short attention span. 2.31 0.66* -
4 You had trouble remembering things 3.74 1 1
5 You felt fatigued. 4.8 1 1
6 You felt happy 4.8 1 1
7 You felt blue or depressed. 5 1 1
8 You enjoyed life 4.8 1 1
9 You worried about little things 2.64 0.66* -
10 You were bothered by being unable to function sexually 4.8 1 0.66*
11 You didn’t have energy to do the things you wanted to do 2.86 0.66* -
12 You were dissatisfied with your sex life 4.8 1 1
13 You were bothered by pain that kept you from doing the things you wanted to do 4.8 1 1
14 You felt tired a lot 1.58 0.66* -
15 You were reluctant to start new relationships 2 1 0.83
16 You lacked interest in sex 4.66 1 1
17 Your mood was disrupted by pain or its treatment 5 1 1
18 You avoided social gatherings 3.87 1 1
19 You were bothered by mood swings 1.75 1 0.83
20 You avoided your friends 2.64 1 0.83
21 You had aches or pains 5 1 1
22 You had a positive outlook on life 4.8 1 0.83
23 You were bothered by forgetting what you started to do 2.52 1 0.83
24 You felt anxious 4.66 1 1
25 You were reluctant to meet new people 1.75 1 0.83
26 You avoided sexual activity 3.18 1 1
27 Pain or its treatment interfered with your social activities 4.5 1 1
28 You were content with your life 4.8 1 1
29 You appreciated life more because of having had cancer 3.45 0.66* -
30 You had financial problems because of the cost of cancer surgery or treatment 3.45 1 1
31 You worried that your family members were at risk of getting cancer 3.45 1 1
32 You realized that having had cancer helps you cope better with problems now 2.41 0.66* -
33 You were self-conscious about the way you look because of your cancer or its treatment 2.52 1 0.66*
34 You worried about whether your family members might have cancer-causing genes 1.66 0.66* -
35 You felt unattractive because of your cancer or its treatment 3.73 1 0.83
36 You worried about dying from cancer 5 1 1
37 You had problems with insurance because of cancer 2.52 1 0.83
38 You were bothered by hair loss from cancer treatment 4.66 1 1
39 You worried about cancer coming back 5 1 1
40 You felt that cancer helped you to recognize what is important in life 1.66 1 0.83
41 You felt better able to deal with stress because of having had cancer 1.98 1 0.88
42 You worried about whether your family members should have genetic tests for cancer 0.99* - -
43 You had money problems that arose because you had cancer 3.32 1 1
44 You felt people treated you differently because of changes to your appearance due to your cancer or its treatment 2.85 1 1
45 You had financial problems due to a loss of income as a result of cancer 3.32 1 1
46 Whenever you felt a pain, you worried that it might be cancer again 3.73 1 1
47 You were preoccupied with concerns about cancer 2.64 1 1
Abbreviations: CVI, content validity index; CVR, content validity ratio
4 Shiraz E-Med J. 2021; 22(2):e100390.
Fathollahi-Dehkordi F et al.
Table 2. QLACS Factor Analysis Results Among Breast Cancer Survivors
Factor 1 Factor 2 Factor 3 Factor Factor 5 Factor Factor 7 Factor 8 Factor 9 Factor 10
Negative/positive feeling
1.You felt happy 0.219 0.232 0.682 0.081 0.077 0.039 0.262 0.036 0.229 -0.071
2.You felt blue or depressed 0.247 0.272 0.542 0.063 0.081 0.198 0.191 0.044 0.35 0.014
3. You enjoyed life 0.147 0.228 0.678 -0.01 0.105 0.192 0.185 0.088 0.331 0.062
4 You were bothered by mood swings 0.114 0.434 0.501 0.034 0.179 0.181 0.236 0.23 0.052 0.176
5. You had a positive outlook on life 0.193 0.181 0.773 0.046 0.188 0.078 -0.011 0.074 0.145 0.214
6. You felt anxious 0.411 0.422 0.438 0.175 0.053 0.188 0.227 0.02 -0.023 0.031
7. You were content with your life 0.166 0.041 0.757 0.036 0.23 0.072 0.152 0.241 -0.2 0.119
Distress/recurrence
8. You worried that your family members were at risk of getting cancer 0.613 0.104 0.066 -0.114 -0.115 -0.001 0.469 -0.141 -0.103 -0.09
9. You worried about dying from cancer 0.803 0.176 0.173 0.078 0.222 0.039 0.04 0.154 0.049 0.054
10. You worried about cancer coming back 0.804 0.054 0.125 0.212 -0.026 0.053 0.075 0.108 0.138 0.081
11. Whenever you felt a pain, you worried that it might be cancer again 0.855 0.04 0.191 0.048 0.021 0.145 0.023 0.195 0.14 0.017
12. You were preoccupied with concerns about cancer 0.813 0.083 0.192 0.085 0.042 0.103 0.085 0.272 0.164 0.019
Social avoidance
13. You were reluctant to start new relationships 0.037 0.659 0.122 0.087 0.02 0.012 0.016 0.18 0.306 0.023
14. You avoided social gatherings 0.098 0.866 0.166 0.044 0.156 0.072 0.122 0.075 -0.029 0.076
15. You avoided your friends 0.09 0.876 0.17 0.069 0.144 0.146 0.012 0.135 -0.016 0.039
16. You were reluctant to meet new people 0.112 0.827 0.162 0.078 0.157 0.14 0.139 0.124 -0.035 -0.029
Financial problem
17. You had financial problems because of the cost of cancer surgery or treatment 0.124 0.107 0.034 0.87 -0.077 0.112 0.136 0.012 -0.031 0.04
18. You had problems with insurance because of cancer 0.043 0.05 -0.01 0.738 0.126 -0.083 0.028 -0.039 0.161 -0.002
19. You had money problems that arose because you had cancer 0.108 0.068 0.083 0.916 -0.089 0.092 0.101 0.096 -0.077 0.099
20. You had financial problems due to a loss of income as a result of cancer 0.033 0.042 0.064 0.864 -0.035 0.028 0.097 0.08 -0.077 0.006
Sexual problem
21. You were dissatisfied with your sex life. 0.047 0.151 0.115 -0.031 0.89 0.003 0.059 -0.052 0.078 0.105
22. You lacked interest in sex 0.059 0.134 0.139 -0.044 0.85 0.126 0.046 -0.088 0.14 0
23. You avoided sexual activity 0.041 0.19 0.28 0.014 0.757 0.094 0.156 0.089 0.156 -0.027
Cognitive problems
24. You had difficulty doing activities that require concentrating. 0.094 0.221 0.172 0.059 -0.043 0.815 0.117 0.03 -0.068 0.067
25. You had trouble remembering things. 0.032 0.041 0.1 0.048 0.081 0.87 0.077 -0.02 0.22 0.133
26. You were bothered by forgetting what you started to do. 0.167 0.123 0.099 0.021 0.187 0.846 0.139 -0.016 0.124 -0.059
Pain
27. You were bothered by pain that kept you from doing the things you wanted to
do.
0.02 0.053 0.075 0.216 0.186 0.156 0.738 0.15 0.221 0.031
28. Your mood was disrupted by pain or its treatment. 0.078 0.275 0.356 0.157 0.127 0.114 0.502 0.186 0.178 0.142
29. You had aches or pains 0.136 0.011 0.266 0.079 0.051 0.16 0.67 0.077 0.166 0.127
30. Pain or its treatment interfered with your social activities. 0.209 0.295 0.196 0.218 0.037 0.061 0.644 0.293 -0.038 0.075
Appearance
31. You felt unattractive because of your cancer or its treatment. 0.179 0.329 0.122 0.019 0.021 -0.01 0.056 0.794 0.024 0.01
32. You were bothered by hair loss from cancer treatment. 0.239 0.033 0.115 -0.012 -0.338 -0.031 0.283 0.612 -0.163 -0.022
33. You felt people treated you differently because of changes to your appearance
due to your cancer or its treatment.
0.224 0.195 0.163 0.128 0.041 0.009 0.16 0.757 -0.037 0.03
Fatigue/energy
34. You had the energy to do the things you wanted to do. 0.182 0.074 0.178 -0.085 0.246 0.088 0.115 -0.059 0.786 0.154
35. You felt fatigued. 0.188 0.011 0.206 0.037 0.176 0.197 0.236 -0.095 0.714 0.062
Benefits
36. You felt that cancer helped you to recognize what is important in life. -0.037 0.045 0.126 0.01 0.092 0.013 0.104 -0.034 0.043 0.901
37. You felt better able to deal with stress because of having had cancer. 0.116 0.054 0.101 0.107 -0.02 0.106 0.058 0.06 0.115 0.856
volved in different aspects of cancer patients to reduce this
effect. Cultural and environmental differences between
countries can be another reason for changing the number
of items. Previous studies had not examined QLACS face
and content validity.
Based on the results of KMO and Bartlett’s test of
sphericity, we could confirm that our data are suitable
to conduct EFA. EFA extracted 10 factors from 37 items.
The Persian version had two factors less than the original
questionnaire. This difference was due to integrating the
recurrence-distress and family distress factors and positive
and negative feelings factors. The Persian version of the
QLACS questionnaire explained 75.8% of the total variance.
This incoherence may be due to the number of items used
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Table 3. QLACS Factors Reliability Among Survivors of Breast Cancer
QLACS Questionnaire Cronbach’s α
Distress-recurrence 0.92
Social avoidance 0.92








for factor analysis. In this study, after face and content va-
lidity stages, 37 items were selected for EFA. Another reason
can be a similar understanding of some sentences in our
language. Also, the difference in target populations can
justify this difference. In this study, breast cancer patients
were studied, but the original questionnaire was used for
different kinds of cancers (6).
We identified a negative, positive dimension: This fac-
tor includes many of the same items as original QLACS
questionnaire positive and negative feeling domains ex-
cept one item ("you were bothered by having a short atten-
tion span."). This item was deleted in the content validity
stage because could not obtain CVR more than 0.99 accord-
ing to panelist opinions for necessary aspect. CVR is depen-
dent on the number of panel specialist. In this study, we
had a panel, including 6 specialists. In previous studies,
CVR was not calculated for QLACS.
We identified a Distress/recurrence dimension: This
factor includes items of the distress- recurrence domain
and one item from the family-distress domain from the
original QLACS questionnaire. Two items from the family
distress domain were deleted in this study. The item "you
were worried about whether your family members should
have genetic tests for cancer" was deleted thein face valid-
ity stage because this item could not obtain sufficient im-
portance score according to the panelists’ opinions. "You
were worried about whether your family members might
have cancer-causing genes" was deleted in the content va-
lidity stage.
We identified a social avoidance dimension: This factor
included the same items as the social avoidance factor in
the original QLACS questionnaire. We also identified a fi-
nancial dimension: This factor included all the items that
were similar to those in the original questionnaire.
We identified a sexual problem dimension: This fac-
tor included three items of the sexual problem domain in
the original questionnaire. One item (“you were bothered
by being unable to function sexually”) was deleted in the
content validity stage according to the panelists’ opinions,
which could be due to cultural issues.
We identified a cognitive problem dimension: This fac-
tor expressed three items of the same factor in the origi-
nal instrument. One Item ("you were bothered by having
a short attention span") was deleted due to CVR less than
0.99.
We identified a pain dimension: This factor was similar
to that in the original instrument.
We identified an appearance concerns dimension: This
factor included all of the items as the original question-
naire except for “you were self-conscious about the way you
look because of your cancer or its treatment”. This item was
deleted because it was not relevant enough according to
the panelists’ opinions.
We identified a fatigue/energy dimension: This factor
expressed two items from the original instrument. Items
“you did not have the energy to do the things you wanted
to do” and “you felt tired a lot” were deleted because of CVR
less than 0.66.
We identified a benefit dimension: This factor included
two items from the original questionnaire. In this study,
two items were deleted from the benefit factor from the
original questionnaire. Items “You appreciate life more be-
cause of having had cancer” and “You realize that having
had cancer helps you cope better with problems now” were
deleted because of CVR less than 0.6 (6).
Previous studies did not apply EFA for the QLACS ques-
tionnaire, which limited our comparisons (3, 9). However,
EFA should be used in the early stages of developing or cor-
recting an instrument (13).
In this study, Cronbach’s alpha was used to evaluate in-
ternal consistency. The range of Cronbach’s alpha was be-
tween 0.74 - 0.93 for different factors of the questionnaire.
The range of Cronbach’s alpha for the original question-
naire factors was between 0.72 - 0.91 that was similar to our
results. In the Spanish version of the questionnaire, the
range of Cronbach’s alpha was between 0.73 and 0.87 (6).
Our results supported that the Persian version of the
QLACS questionnaire has suitable properties for evaluat-
ing the quality of life among short survivors of breast can-
cer.
5.1. Limitations
There were some limitations to this study. According to
the specialist panel’s suggestions, face and content valid-
ity were determined so it can change by changing the spe-
cialist panel. For further studies, we suggest a panel group
with a greater number of specialists to reduce this effect.
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In this study, we used EFA for construct validity. For fur-
ther studies we recommend confirmatory factor analysis
for confirming our findings.
5.2. Conclusion
According to the results, the Persian version of the
QLACS questionnaire has optimal properties for assessing
the quality of life among Iranian short-survivors of breast
cancer.
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